Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation
- PMID: 10408412
- PMCID: PMC2363093
- DOI: 10.1038/sj.bjc.6690575
Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation
Abstract
We have previously shown that, in asymptomatic post-menopausal women, serum CA125 elevation is associated with a 36-fold increase in risk of ovarian cancer. This study was undertaken to assess the value of pelvic ultrasound for further stratification of ovarian cancer risk. Of 22,000 post-menopausal women, aged > or = 45 participating in an Ovarian Cancer Screening Trial, 741 with a CA125 > or = 30 U ml(-1) underwent pelvic ultrasonography. Twenty index cancers (primary invasive epithelial carcinomas of the ovary and fallopian tube) were diagnosed amongst these 741 women during a median follow-up of 6.8 years. Ultrasound results separated the women with CA125 elevation into two groups. Those with normal ovarian morphology had a cumulative risk (CR) of index cancer of 0.15% (95% confidence interval (CI) 0.02-1.12) which is similar to that of the entire population of 22,000 women (0.22%, 95% CI 0.18-0.30). In contrast, women with abnormal ovarian morphology had a CR of 24% (15-37) and a significantly increased relative risk (RR) of 327 (156-683). Ultrasound can effectively separate post-menopausal women with raised CA125 levels into those with normal scan findings who are not at increased risk of index cancer and those with abnormal findings who are at substantially increased risk of index cancer.
Similar articles
-
Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.BJOG. 2014 Dec;121 Suppl 7:35-9. doi: 10.1111/1471-0528.13211. BJOG. 2014. PMID: 25488086
-
Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.BJOG. 2000 Feb;107(2):165-9. doi: 10.1111/j.1471-0528.2000.tb11685.x. BJOG. 2000. PMID: 10688498
-
Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less.Gynecol Obstet Invest. 2008;65(2):133-8. doi: 10.1159/000110014. Epub 2007 Oct 23. Gynecol Obstet Invest. 2008. PMID: 17957102
-
The role of transvaginal ultrasound in screening for ovarian cancer.Climacteric. 2018 Jun;21(3):221-226. doi: 10.1080/13697137.2018.1433656. Epub 2018 Mar 1. Climacteric. 2018. PMID: 29490504 Review.
-
[Ovarian tumor markers of presumed benign ovarian tumors].J Gynecol Obstet Biol Reprod (Paris). 2013 Dec;42(8):752-9. doi: 10.1016/j.jgyn.2013.09.030. Epub 2013 Nov 7. J Gynecol Obstet Biol Reprod (Paris). 2013. PMID: 24210243 Review. French.
Cited by
-
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.Br J Cancer. 2004 Apr 19;90(8):1492-7. doi: 10.1038/sj.bjc.6601692. Br J Cancer. 2004. PMID: 15083174 Free PMC article.
-
Ascites and a raised serum Ca 125--confusing combination.J R Soc Med. 2001 Nov;94(11):581-2. doi: 10.1177/014107680109401107. J R Soc Med. 2001. PMID: 11691896 Free PMC article. No abstract available.
-
Treatment guidelines in ovarian cancer.Clin Transl Oncol. 2007 May;9(5):308-16. doi: 10.1007/s12094-007-0058-8. Clin Transl Oncol. 2007. PMID: 17525041
-
Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis.Int J Clin Oncol. 2009 Oct;14(5):378-82. doi: 10.1007/s10147-009-0931-2. Epub 2009 Oct 25. Int J Clin Oncol. 2009. PMID: 19856043 Review.
-
The role of biomarkers in the management of epithelial ovarian cancer.Expert Rev Mol Diagn. 2017 Jun;17(6):577-591. doi: 10.1080/14737159.2017.1326820. Epub 2017 May 15. Expert Rev Mol Diagn. 2017. PMID: 28468520 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous